Navigation Links
NUCRYST Pharmaceuticals announces year-end results
Date:2/14/2008

482

Foreign currency

translation

adjustments - (209) (209)

Net loss (10,499) (10,499) (10,499)

-------------------------------------------------------------

December 31, 2006 (34,078) (10,708) 43,586

Issuance of common

shares in connection

with restricted

shares and exercises

of stock options - - 104

Stock-based

compensation - - 1,029

Foreign currency

translation

adjustments - 6,047 6,047

Net loss (4,021) (4,021) (4,021)

-------------------------------------------------------------

December 31, 2007 $ (38,099) $ 2,026 $ 46,745

-------------------------------------------------------------

-------------------------------------------------------------


'/>"/>
SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. NUCRYST Pharmaceuticals announces 2007 third quarter results
2. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. NUCRYST and Smith & Nephew Revise Agreements
4. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
5. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
6. Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
7. American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals
8. MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product
9. Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program
10. Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer
11. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...rter financial results -, LAVAL, QC, July 25 /PRN...DAQ: DDSS) today announced that it will host a con... to discuss its second quarter 2008,financial resu... financial,results via news release at approximate...nce call by telephone, dial 416-646-3095 or,1-800-...
(Date:7/25/2008)...erweight or obese is not only a personal issue tha... issue that impacts other people in society. A new...eveals that the extra Medicare cost associated wit...ant financial burden on tax payers, costing up to ...current Medicare population. , The article,s fi...
(Date:7/25/2008)...Fourth Annual Physician On-Call Pay ...swire/ -- Sullivan, Cotter and Associates, Inc.,ha...on-call pay rates and,practices, the 2008 Physicia...th data from 132 healthcare organizations nationwi...ates paid for 33 physician specialty areas along,w...
(Date:7/25/2008)...ire/ -- Sagent Pharmaceuticals, Inc.,a privately-...nced that it,has launched amiodarone HCl injection...e treatment and prophylaxis of frequently recurrin...table ventricular,tachycardia -- a potentially lif...arone HCl injection will be available immediately ...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
... U.S. is getting metamorphosed into luxurious buil...ipments which may offer good patient hospitality b...g to non-accessible of poor patients to these luxu...s changing from a semi-private health system to co...
...licy to Briton citizen could increase advertising ...y is aimed at // reducing the waiting time of th...eople can make their own choice of treatment at an... their comfortable location and choice. Health Sec...
...hat is mainly present in pain relievers. Recently ...ing the // clinicians complaining about over dosa...re of the liver but about 50% of these cases are u...yl, Contac, Excedrin, Robitussin, Nyquil and Sinut...
...ty of California have now established a very stron...ure, or end-stage renal disease. So if you are thi...away, as there is no time to lose. // "There are...ure, but it hasn't been appreciated much that kidn...
Other Medicine News:Health News:Painkillers Lead To Liver Failure 2
(Date:7/24/2008)... New JIT Enrollment Program Speeds Oncology... Pharmatech, Inc., a Research Management,Organizat...ceutical,companies to provide research and site ma...the Just-in-Time (JIT) enrollment strategy. The ne...: follicular Non-Hodgkin,s,Lymphoma, Metastatic Br...
(Date:7/24/2008)... NEW YORK, July 24 /- Mac...y announced results of a Phase 2 clinical trial,in...multi-center,open-label efficacy and safety study...treatment of onychomycosis (nail fungus). The comp...complete cure" defined as,negative mycology (negat...
(Date:7/23/2008)... - Nexavar is First Approved Systemic Therapy to... Calif., July 23 /-,Bayer H..., Inc. (Nasdaq:,ONXX) today announced that The New...a Phase 3 trial demonstrating that Nexavar(R) (sor...th by 31 percent in patients with,unresectable hep...
(Date:7/23/2008)... SEATTLE, July 23 /- Sound Pharmace...g Application with the FDA for the clinical,testin...prevention of,chemotherapy induced hearing loss or... SPI-3005, will be tested in advanced stage lung c...platinum based chemotherapy.,This marks the second...
Breaking Medicine Technology:Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Rocky water source 3607 1Rocky water source 3607 2Sex offenders register provides limited protection for children 21576 1Sex offenders register provides limited protection for children 21576 2Raloxifene Cuts Risk of Certain Type of Breast Cancer 21573 1Raloxifene Cuts Risk of Certain Type of Breast Cancer 21573 2Harris Corporations Jim Traficant Addresses Florida Agency for Health Care Administration 21570 1Harris Corporations Jim Traficant Addresses Florida Agency for Health Care Administration 21570 2
LigaSure system generator, bipolar only. Designed to permanently seal vessels and tissue bundles.
Sabre 180 is a powerful niche generator.
Sabre 180 is a powerful niche generator.
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator.
Medicine Products: